Scientist, In Vivo Pharmacology
Earli
About Earli
Earli exists to make cancer a benign experience. Earli does that by turning cancers against themselves: genetically forcing them to reveal themselves early, and then kill themselves – precisely and clearly distinguishable from benign lesions at early stages. Based on original technology from Stanford’s renowned Gambhir lab, Earli designs genetic constructs that are injected intravenously that turn cancer cells against themselves. These programmable synthetic promoter-reporter sequences “flip on” like light switches only in dysregulated cancer cells and turn them into "factories." The cancer is forced to produce either an epitope “docking station” for imaging agents, or a cytokine for immune system activation against the tumor. Thus, Earli’s platform enables immediate diagnosis and treatment of early cancers, rather than long-term observation that can lead to deadly metastatic recurrence.
Earli's synthetic target expression platform has evolved over five years of deep bioengineering. The system can now detect broad ranges of patient mutations, distinguish between malignant and benign lesions, and offer independence from often elusive natural biomarkers.
Earli has raised $82m in three rounds from investors including Andreessen Horowitz, Khosla Ventures, Emerson Collective, Stanford, Perceptive Advisors, Casdin Capital, Marc Benioff, Sands Capital, Breyer Capital, Tailwinds (American-Korean) etc.
Its Scientific Advisory Board includes Jim Allison (Nobel Laureate, Immuno Oncology), Bob Langer (MIT, co-founder Moderna), Phil Greenberg (Hutch, co-founder Juno), Pam Sharma (MD Anderson), Charlie Rudin (Sloan Kettering), Alan Ashworth (UCSF Cancer Center).
Who You Are
- You share our same sense of dedication, scientific passion and entrepreneurial spirit
- You work well in a fast-paced and extremely focused startup environment
- You are not only smart, but clever and constantly think outside the box
- You are able to make logical decisions in an instant when there is little time to evaluate
- You are a natural communicator and relationship builder
- You stay calm under high pressure and stress
- You have the ability to multi-task in a serious way, with an extreme attention to detail
- You become a representative of the core DNA of the company through who you are
The Position
Earli is seeking a passionate, creative, and dedicated Scientist to join our in vivo pharmacology team. In this role, you will be pivotal in supporting the development of our cancer-activated gene expression platform utilizing animal models. Under the guidance of the Director of Translational Biology, your work will directly lead projects answering scientific challenges across functions. As a rapidly growing biotech company, we offer an exciting and collaborative work environment where every team member plays a vital role in our success.
Your Primary Responsibilities
- Design, plan, perform, and analyze rodent in vivo experiments testing our cancer detection products with a high degree of independence
- Identify, pilot out and develop new oncology murine models relevant to Earli platform and programs
- Work closely with Earli’s formulation and bioanalytical groups to assist in coordinating studies
- Act as in vivo subject matter expert on project team meetings
- Present results at group and department meetings
- Manage one or two direct reports
- Biochemical/Molecular analysis of tissues and plasma (i.e. qPCR, Luminex)
- Maintaining familiarity with current scientific literature, routinely dive into topics quickly and develop a broad and relatively deep grasp of new research areas
Your Required Experience, Knowledge and Skill
- PhD degree in biology, pharmacology, or other relevant field is required with at least 1 year of experience in in vivo pharmacology studies in a pharmaceutical company. Applicants with Master degree and at least 5 years of relevant industry experience will be considered.
- Possess a very good depth of expertise within in vivo oncology research with a proven track of successful projects contributing to cancer research questions
- Actively keep up with literature and critically use knowledge to inform the definition & scope of new projects, define hypotheses & alternative methods
- This role is estimated to be 75% bench-focused and high proficiency in animal-related techniques is essential, including dosing via multiple routes (IV, PO, IP, SC), biological sample collection (blood collection and necropsies), tumor cell culture, inoculation and bioluminescence imaging.
- This role is estimated to be 25% of project and team management. Ability to parallelize tasks to progress simultaneously multiple projects is required. Previous experience mentoring junior team members on the project side and advising on troubleshooting is preferred.
- Commitment to high-quality work and best animal research use practices is essential
- Experience with biochemical and/or molecular techniques is an advantage
- Strong communication skills that enable the individual to interact with all levels of management, technical and scientific personnel
- Strong sense of scientific rigor, integrity, and curiosity
- Proficient with basic computer programs routinely used in a lab such as MS Word, Excel, and PowerPoint, GraphPad Prism
- Highly organized with reliable time-keeping skills and able to maintain a detailed documentation
- Ability to work in a team-oriented and fast-paced environment
The base salary $110-$130k per year
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!